Details of the Drug Combination

General Information of Drug Combination (ID: DC4G9WA)

• Drug Combination Name: Metaxalone + 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Metaxalone (DMXLZP6): Small molecular drug
  1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole (DMQEJVU): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 6.28
  Bliss Independence Score: 6.28
  Loewe Additivity Score: 20.45
  LHighest Single Agent (HSA) Score: 20.45

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Metaxalone

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[2]

Indication(s) of 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole

Disease Entry	ICD 11	Status	REF
Conjunctival fibrosis	9A61.3	Investigative	[3]

1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Calcium-activated potassium channel (KCN)	TTMNI76	NOUNIPROTAC	Inhibitor	[4]
Calcium-activated potassium channel KCa3.1 (KCNN4)	TT7M9I6	KCNN4_HUMAN	Blocker (channel blocker)	[5]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7609).
• [3] Blockade of KCa3.1: A novel target to treat TGF-1 induced conjunctival fibrosis.Exp Eye Res. 2018 Feb;167:140-144.
• [4] Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
• [5] Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.